Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 4, 2009, Pages 1118-1124

  De Bruin, Christiaan ^a   Pereira, Alberto M ^b   Feelders, Richard A ^a   Romijn, Johannes A ^b   Roelfsema, Ferdinand ^b   Sprij Mooij, Diane M ^a   Van Aken, Maarten O ^a   Van Lelij, Aart Jan Der ^a   De Herder, Wouter W ^a   Lamberts, Steven W J ^a   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR; MESSENGER RNA; SOMATOSTATIN RECEPTOR;

ACTH SECRETING ADENOMA; ADENOIDECTOMY; ADOLESCENT; ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERCORTISOLISM; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 65249166135     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-2101     Document Type: Article

References (26)

1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK 2006 Cushing's syndrome. Lancet 367:1605-1617
2. Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, Laws Jr ER 2008 Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93:358-362
3. Morris D, Grossman A 2002 The medical management of Cushing's syndrome. Ann NY Acad Sci 970:119-133
4. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Holland LJ, Lamberts SW 2004 Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452-2462
5. Pivonello R, De Martino MC, Cappabianca P, de Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A 2009 The medical treatment of Cushing's disease: effectiveness of chronic treatment with the do- pamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94:223-230
6. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645-654
7. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A 2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482-4488
8. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J 2009 Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand soma- tostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94:115-122
9. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC 2000 Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154-157
10. Saveanu A, Jaquet P 24 July 2008 Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord 10.1007/s11154-008-9086-0
11. de Bruin C, Hanson JM, Meij BP, Kooistra HS, Waaijers AM, Uitterlinden P, Lamberts SW, Hofland LJ 2008 Expression and functional analysis of dopa- mine receptor subtype 2 and somatostatin receptor subtypes in canine Cush- ing's disease. Endocrinology 149:4357-4366
12. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW 2004 The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89:1577-1585
13. Rasmussen R 2001 Quantification on the LightCycler. In: Meuer S, Wittwer C, Nagakawara K, eds. Rapid cycle real-time PCR, methods and applications. Heidelberg, Germany: Springer Press; 21-34
14. Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
15. Hofland LJ, Liu Q, Van Koetsveld PM, Zuijderwijk J, Van Der Ham F, De Krijger RR, Schonbrunn A, Lamberts SW 1999 Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human soma- tostatin receptor positive tumors. J Clin Endocrinol Metab 84:775-780
16. Greenman Y, Ouaknine G, Veshchev I, Reider G, II, Segev Y, Stern N 2003 Postoperative surveillance ofc linically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin Endocrinol (Oxf) 58:763-769
17. Hofland LJ, Lamberts SW 2003 The pathophysiological consequences of so- matostatin receptor internalization and resistance. Endocr Rev 24:28-47
18. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno O, Lacroix A, Long-term therapy with cabergoline in Cushing's disease. Program of the 90th Annual Meeting of The Endocrine Society, San Francisco, CA, 2008 (P2-130)
19. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U 2007 Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 19:2304-2316
20. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P 2002 Demonstration ofenhanced potencyofa chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 87:5545-5552
21. RenSG, KimS, Taylor J, Dong J, Moreau JP, Culler MD, MelmedS 2003 Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/ dopaminergic chimeric ligand. J Clin Endocrinol Metab 88:5414-5421
22. Blevins Jr LS, Christy JH, Khajavi M, Tindall GT 1998 Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitarymacroad- enomas. J Clin Endocrinol Metab 83:63-67
23. Katznelson L, Bogan JS, Trob JR, Schoenfeld DA, Hedley-Whyte ET, Hsu DW, Zervas NT, Swearingen B, Sleeper M, Klibanski A 1998 Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab 83:1619-1623
24. Bochicchio D, LosaM, Buchfelder M1995 Factors influencing theimmediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 80:3114-3120
25. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ 2005 Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 289:E278-E287
26. 2 and soma- tostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol 42:47-56